{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rao VS"],"funding":["NHLBI NIH HHS","National Institutes of Health","AstraZeneca"],"pagination":["340-346"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10947725"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(2)"],"pubmed_abstract":["<h4>Background and objectives</h4>Approaches to distinguishing pathological cardiorenal dysfunction in heart failure (HF) from functional/hemodynamically mediated changes in serum creatinine are needed. We investigated urine galectin-3 as a candidate biomarker of renal fibrosis and a prognostic indicator of cardiorenal dysfunction phenotypes.<h4>Methods</h4>We measured urine galectin-3 in 2 contemporary HF cohorts: the Yale Transitional Care Clinic (YTCC) cohort (n = 132) and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial (n = 434). We assessed the association of urine galectin-3 with all-cause mortality in both cohorts and the association with an established marker of renal tissue fibrosis, urinary amino-terminal propeptide of type III procollagen (PIIINP) in TOPCAT.<h4>Results</h4>In the YTCC cohort, there was significant effect modification between higher urine galectin-3 and lower estimated glomerular filtration rates (eGFRs) (P<sub>interaction</sub> = 0.046), such that low eGFR levels had minimal prognostic importance if urine galectin-3 levels were low, but they were important and indicated high risk if urine galectin-3 levels were high. Similar observations were noted in the TOPCAT study (P<sub>interaction</sub> = 0.002). In TOPCAT, urine galectin-3 also positively correlated with urine PIIINP at both baseline (r = 0.43; P < 0.001) and at 12 months (r = 0.42; P < 0.001).<h4>Conclusions</h4>Urine galectin-3 levels correlated with an established biomarker of renal fibrosis in 2 cohorts and was able to differentiate high- vs low-risk phenotypes of chronic kidney disease in HF. These proof-of-concept results indicate that additional biomarker research to differentiate cardiorenal phenotypes is warranted."],"journal":["Journal of cardiac failure"],"pubmed_title":["Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure."],"pmcid":["PMC10947725"],"funding_grant_id":["R21 HL143092","K23 HL114868","L30 HL115790","R01HL128973","R01 HL128973","L30HL115790","R01HL148354","K23HL114868","R01HL139629","R01 HL148354","R21HL143092","R01 HL139629"],"pubmed_authors":["Cox ZL","Ivey-Miranda JB","Moreno-Villagomez J","Rao VS","Testani JM"],"additional_accession":[]},"is_claimable":false,"name":"Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure.","description":"<h4>Background and objectives</h4>Approaches to distinguishing pathological cardiorenal dysfunction in heart failure (HF) from functional/hemodynamically mediated changes in serum creatinine are needed. We investigated urine galectin-3 as a candidate biomarker of renal fibrosis and a prognostic indicator of cardiorenal dysfunction phenotypes.<h4>Methods</h4>We measured urine galectin-3 in 2 contemporary HF cohorts: the Yale Transitional Care Clinic (YTCC) cohort (n = 132) and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial (n = 434). We assessed the association of urine galectin-3 with all-cause mortality in both cohorts and the association with an established marker of renal tissue fibrosis, urinary amino-terminal propeptide of type III procollagen (PIIINP) in TOPCAT.<h4>Results</h4>In the YTCC cohort, there was significant effect modification between higher urine galectin-3 and lower estimated glomerular filtration rates (eGFRs) (P<sub>interaction</sub> = 0.046), such that low eGFR levels had minimal prognostic importance if urine galectin-3 levels were low, but they were important and indicated high risk if urine galectin-3 levels were high. Similar observations were noted in the TOPCAT study (P<sub>interaction</sub> = 0.002). In TOPCAT, urine galectin-3 also positively correlated with urine PIIINP at both baseline (r = 0.43; P < 0.001) and at 12 months (r = 0.42; P < 0.001).<h4>Conclusions</h4>Urine galectin-3 levels correlated with an established biomarker of renal fibrosis in 2 cohorts and was able to differentiate high- vs low-risk phenotypes of chronic kidney disease in HF. These proof-of-concept results indicate that additional biomarker research to differentiate cardiorenal phenotypes is warranted.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-05T10:19:40.313Z","creation":"2025-04-05T10:19:40.313Z"},"accession":"S-EPMC10947725","cross_references":{"pubmed":["37301248"],"doi":["10.1016/j.cardfail.2023.05.018"]}}